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Abstract
Objective: In this multicenter study, we investigated the management algorithm for thyroid nodules with benign cytology
using US features from data collected from 7 institutions.
Materials and Methods: The institutional review board approved this retrospective study. Data on 700 focal thyroid nodules
in 673 consecutive patients were collected from 7 university-affiliated hospitals. This study included nodules that were
diagnosed as benign at initial cytologic evaluation and that underwent pathologic or follow-up study. The risk of
malignancy was compared according to the US assessments of each institution as well as looking at all the nodules together
as a whole.
Results: Of the 700 nodules, 688 (98.3%) were benign and 12 (1.7%) were malignant. If initial cytologic results were benign,
the likelihood of the nodule actually being malignant was from 1 to 3%, varying by institution. The likelihood of a
cytologically benign nodule with positive US being malignant (4.7%, 8/169) was higher than that of one without positive US
(0.8%, 4/531) (P= .002).
Conclusion: Based on our multicenter study, repeat FNA should be performed in thyroid nodules with initial benign
cytology showing suspicious US features in order to decrease the number of false negative cases.
Citation: Choi YJ, Jung I, Min SJ, Kim HJ, Kim J-h, et al. (2013) Thyroid Nodule with Benign Cytology: Is Clinical Follow-Up Enough? PLoS ONE 8(5): e63834.
doi:10.1371/journal.pone.0063834
Editor: Apar Kishor Ganti, University of Nebraska Medical Center, United States of America
Received January 10, 2013; Accepted April 7, 2013; Published May 24, 2013
Copyright:  2013 Choi et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The authors have no support or funding to report.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: docjin@yuhs.ac
Introduction
In the diagnosis of focal thyroid lesions, ultrasound (US) and
US-guided fine-needle aspiration (US-FNA) have become widely
used, routine procedures that decide the direction of further
management [1–4]. Although US-FNA is an operator-depen-
dent diagnostic tool, it definitely shows higher diagnostic
accuracy compared to palpation-guided FNA [5]. Also US
shows relatively good interobserver agreement in reaching a
final assessment, especially among experienced physicians [6–8].
A thyroid nodule with benign cytology carries about 0–3% risk
of malignancy, thus clinical follow up is recommended over
repeat FNA [9–11]. However, the risk of malignancy in a
thyroid nodule with benign cytology varies among institutions,
with reported values being between a wide range of 2% to 18%
[12]. Therefore, recommendations in the management of these
nodules vary from routine follow up to repeat FNA. Although
some papers have demonstrated a selection approach based on
US features for repeat FNA in benign thyroid nodules [13–15],
whether this approach may be generally reproducible in other
institutions has not been verified. In this multicenter study, we
retrospectively investigated the management algorithm for
thyroid nodules with benign cytology using US features from
data collected from 7 different institutions.
Materials and Methods
The institutional review board of severance hospital approved of
this retrospective observational study and required neither patient
approval nor informed consent for our review of patients’ images
and patients’medical records. However, written informed consent
was obtained from all patients for US-FNA prior to each
procedure as a daily practice.
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Study Population
Study subjects were collected from 7 institutions of the Korean
Society of Thyroid Radiology group. Seven radiologists with more
than 3 years of experience in thyroid imaging participated in
patient collection and review. Each institution contributed 100
consecutive thyroid nodules equal to or larger than 1 cm with
benign cytology at initial FNA for this multicenter study. Patients
were included according to the following criteria: (a) patients who
underwent thyroid surgery, (b) patients who had at least 2
consecutive US-FNA sessions in which both results showed benign
cytology, and (c) patients with benign initial cytology who had no
interval change or decreased size on follow-up US performed at
least 1 year from March 2007. After applying the inclusion
criteria, this study finally included 700 thyroid nodules in 673
patients. Size increase was defined as more than 50% increase in
volume or more than 20% increase in at least two dimensions that
showed a minimum 2 mm increase in solid nodules or the solid
portion in mixed cystic–solid nodules [9,15–19].
Patient age ranged from 11 to 91 years (mean, 52.3 years).
Mean age was 54.3 years (range, 11–84 years) in men, and 52
years (range, 13–91 years) in women. Mean nodule size was
20.3610.5 mm (range, 10–49 mm).
Imaging and Imaging Analyses
To evaluate thyroid nodules, US images were taken using
various US machines with high frequency linear array transducers.
Scanning protocol in all cases included both transverse and
longitudinal real-time imaging of thyroid nodules, with the use of
representative Digital Imaging and Communications in Medicine
(DICOM) images.
For analysis of US images, participating radiologists were asked
to assess thyroid nodules according to criteria from previously
published literature [9–11,20–26]. The criteria used in analysis
included the echogenicity of solid portion, orientation, shape,
margin, and calcifications. Echogenicity was classified as hyper-,
iso-, or hypoechogenicity (when a nodule showed hyper-, iso-, or
hypoechogenicity compared to the normal thyroid gland), or
marked hypoechogenicity (when a nodule showed relative
hypoechogenicity compared to the surrounding strap muscle).
Margin was classified as well defined or not-well defined
(microlobulated or irregular margin). Calcifications were classified
as microcalcification (equal to or less than 1 mm in diameter; tiny,
punctate, hyperechoic foci, either with or without acoustic
shadows), macrocalcification including rim or eggshell calcifica-
tion, or no calcification. When the nodules had both types of
calcifications (macrocalcifications including rim calcifications
intermingled with microcalcifications), the nodule was considered
to have microcalcifications. Shape was classified as wider than tall
or taller than wide. Suspicious malignant gray scale US features
included marked hypoechogenicity, not-well defined margin,
microcalcifications, and taller than wide shape. When thyroid
nodules showed one or more of the above suspicious malignant
gray scale US features, they were assessed as ‘‘positive’’. When
thyroid nodules showed no suspicious features, they were assessed
as ‘‘negative’’ [15,17–19,21].
Data and Statistical Analysis
Histopathologic results from surgical pathology or repeat US-
FNA with follow-up US were used as standard reference.
Categorical data were summarized using frequencies and
percentages. We compared patients with benign or malignant
thyroid nodules according to gender and US grouping using
Fisher’s exact test. The independent two-sample t-test was used to
evaluate the association between patient age or nodule size to
malignancy. Malignancy rate was compared according to US
groupings using Fisher’s exact test.
Analysis was performed with SAS software (version 9.2; SAS
Institute, Cary, NC). Statistical significance was assumed when the
P value was less than 0.05. All reported P values are 2-sided.
Results
Table 1 shows the baseline characteristics of the patients
included in this study. Age, gender, and tumor size were not
significantly different between malignant and benign nodules.
Table 1. Baseline characteristics of 700 thyroid nodules in
673 patients.
Malignant
(n =12)
Benign
(n=688) P
Mean age (years) 52.769.7 52.3612.2 0.907
Gender 1
Men 1 (8.3%) 85 (12.4%)
Women 11 (91.7%) 603 (87.6%)
Mean nodule size (mm) 20.3618.3 20.3610.3 0.907
US assessment 0.002
Positive 8 (66.7%) 161 (76.6%)
Negative 4 (33.3%) 527 (23.4%)
doi:10.1371/journal.pone.0063834.t001
Table 2. Histopathologic Results of the 89 Nodules confirmed by Surgery.
Histopathologic result Number Percentage
Malignant (n = 12) Papillary carcinoma 6 50
Follicular variant of papillary carcinoma 3 25
Minimally invasive follicular carcinoma 2 16.7
Minimally invasive Hurthle cell carcinoma 1 8.3
Benign (n = 77) Adenomatous hyperplasia 66 85.7
Follicular adenoma 7 9.1
Hashimoto’s thyroiditis 4 5.2
doi:10.1371/journal.pone.0063834.t002
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However, US assessments were significantly different between
malignant and benign nodules (P= .002).
Of the 700 nodules included, 688 (98.3%) were benign and 12
(1.7%) were malignant. Among the total collected data, 89 cases
were confirmed by surgical pathology (Table 2). Malignant rates
were equal to or less than 3% in thyroid nodules with benign
cytology, regardless of institution (Table 3). In nodules with benign
cytology which did not have positive US, malignant rates were
equal to or less than 1.5% in all 7 institutions. In 5 of the 7
institutions, malignant rates were more than 3% in nodules with
positive US and were higher than those without. When analyzing
all the 700 thyroid nodules with benign cytology from the 7
institutions together as a whole, the likelihood (4.7%, 8/169) of a
cytologically benign nodule with positive US actually benign
malignant was higher than that (0.8%, 4/531) of one without
positive US (P= .002, Table 3).
Discussion
There are several management approaches accepted for thyroid
nodules with benign cytology [27–30]. The American Thyroid
Association (ATA) recommends that all benign thyroid nodules be
followed with serial US examinations performed 6–18 months
after the initial FNA [9]. If the nodule size is stable (i.e., no more
than a 50% change in volume or less than 20% increase in at least
two nodule dimensions in solid nodules or in the solid portion of
mixed cystic–solid nodules), the interval before the next clinical
examination or US may be longer, e.g., every 3–5 years. If there is
evidence for nodule growth either by palpation or US (more than
a 50% change in volume or a 20% increase in at least two nodule
dimensions with a minimal increase of 2 mm in solid nodules or in
the solid portion of mixed cystic–solid nodules), FNA should be
repeated, preferably with US guidance. The American Association
Clinical Endocrinologists/Associazione Medici Endocrinologi
(AACE/AME) suggests only simple clinical follow-up without
US in patients with thyroid nodules with benign cytology as long
as they do not present with clinical problems [11]. The Bethesda
guidelines also suggest that as the malignant rate of benign
cytology can be less than 3% [31], clinical follow-up may be
enough for further evaluation. These recommendations are based
on the belief that a thyroid nodule with benign cytology has a very
low malignant rate. However, false negative rates of thyroid
nodules with benign cytology have been reported to be relatively
higher (more than 10%) than expected in some institutions
[32,33], supporting the necessity of repeat FNA in nodules with
benign cytology.
Recently, several reports have proposed combining US and
cytology results in management decisions of thyroid nodules, and
repeat FNA may be selectively performed in thyroid nodules with
benign cytology which show suspicious US features [13–15,19,28].
Investigations into selecting repeat FNA as a management
approach for thyroid nodules with benign cytology using US
features have been done and reported on in a few institutions
[13,28,34,35]. Therefore, we investigated the management algo-
rithm for thyroid nodules with benign cytology using US features
from data collected from multiple institutions. This study
demonstrated a malignancy rate of 1.7% in thyroid nodules with
initial benign cytology, and most institutions showed higher
malignancy rates in nodules showing suspicious US features (0–
28.6%) compared to those without any suspicious US features (0–
1.5%). With the provided data of our multicenter study, it makes
sense to select nodules according to US features, resulting in
reduction of unnecessary repeat FNAs, while not overlooking
malignancy among thyroid nodules with benign cytology on initial
FNAs.
There were several limitations to this study. First, selection bias
may have existed when choosing patients to enroll in this study.
Patients who had not undergone follow-up after initial benign
cytology or surgery after malignant cytology results were not
included in this study. Second, the interobserver variability in US
image interpretation among the 7 radiologists was not evaluated.
In a multicenter study, several factors such as using different US
equipment, as well as an inevitable interobserver variability can
affect the final assessment of thyroid nodules. In order to minimize
this limitation, the same reference standards published in previous
reports were used [17,20,23]. Third, when we compared
malignant rates according to US positive and US negative among
the 7 institutions, only 1 institution had a significantly higher
malignancy rate, while others did not show significant differences.
This may be due to the small skewed sample size. The total
number of higher malignant rates was statistically significant in
nodules with positive US.
In conclusion, based on our multicenter study, repeat FNA
should be performed in thyroid nodules with initial benign
cytology showing suspicious US features in order to decrease the
number of false negative cases.
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Table 3. Likelihood of a Thyroid Nodule with Initial Benign Cytology Being Malignant According to each Institution.
Institutions
Likelihood of Nodule
Being Malignant (%)
Likelihood of Nodule with
Negative US Being Malignant (%)
Likelihood of Nodule with
Positive US Being Malignant (%) P value
A 2 0 (0/93) 28.6 (2/7) 0.004
B 1 1.5 (1/68) 0 (0/32) 1
C 2 0 (0/37) 3.2 (2/63) 0.529
D 1 1 (1/96) 0 (0/4) 1
E 2 1.3 (1/78) 4.5 (1/22) 0.393
F 3 1.3 (1/75) 8 (2/25) 0.153
G 1 0 (0/84) 6.3 (1/16) 0.16
Total 12 0.8 (4/531) 4.7 (8/169) 0.002
doi:10.1371/journal.pone.0063834.t003
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